search icon
  • Print
  • ShareThis
  • Text Size
  • Federal Funding for Infectious Diseases Programs

    Funding

    Today’s investment in ID research; public health and prevention; and development of new drugs, vaccines and diagnostics will pay significant dividends in the future. Such investments can prevent needless deaths, dramatically reduce health care costs, and improve the quality of life for millions of Americans and others around the world.  IDSA supports appropriate funding for domestic and international programs including those at the:

    • National Institute for Allergies and Infectious Diseases 
    • Centers for Disease Control and Prevention  
    • Food and Drug Administration 
    • Health Resources Services Administration 
    • U.S. Agency for International Development 
    • National Institute of Health’s Fogarty International Center 

     

    IDSA’s funding priorities include antimicrobial resistance; immunizations; drug, vaccine and diagnostics development; and HIV/AIDS and tuberculosis prevention and treatment.

     

    See also:

    HIVMA Federal Funding

    IDSA's Efforts in Advocating for Appropriate Federal Funding for Infectious Diseases Programs

    11/12/2014

    IDSA Provides Testimony for Senate Hearing on Ebola Funding (PDF)

    IDSA provided testimony to the Senate Appropriations Committee in support of President Obama's request for emergency funds to deal with the Ebola outbreak.  The Committee solicited stakeholder input ahead of a hearing to discuss the President's request.
    4/24/2014

    IDSA Provides Testimony on Innovation to the Senate (PDF)

    In preparation for a Senate hearing on the federal role in promoting innovation, IDSA provided testimony on the health and economic gains possible from new public health strategies, vaccines, antibiotics, and rapid diagnostics.
    3/25/2014

    IDSA Provides Testimony to Congress in Support of Funding for ID Priorities (PDF)

    IDSA provided testimony that stressed the need for federal funding of ID priorities.  The testimony--which touched on areas such as antimicrobial resistance, antibiotic and rapid diagnostic R&D, and immunizations--is the first in a series of advocacy activities that will be taken to engage Congress on the FY15 budget.
    5/6/2013

    IDSA Senate Testimony on Fiscal Year 2014 Funding for the Department of Health and Human Services (PDF)

    IDSA submitted testimony to the Senate Appropriations Committee regarding FY 2014 funding for the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA)
    11/12/2014

    IDSA Joins Groups in Calling Attention to Innovation Deficit (PDF)

    IDSA joined 132 other organizations from the health, science, higher education, and business communities in a letter to Congress urging finalization of the FY 2015 appropriations bills in order to avoid exacerbating the nation's innovation deficit.
    10/27/2014

    IDSA Leads 55 Organizations in Effort to Support Funding for Antibiotic Resistance Initiatives (PDF)

    IDSA was joined by 55 other organizations in a letter to the White House Office of Management and Budget (OMB) in support of new funding to address antibiotic resistance as called for by the President's Council of Advisors on Science and Technology
    10/1/2014

    IDSA Joins in Advocacy for Implementation of Food Safety Modernization Act (PDF)

    IDSA and fifteen other public health groups joined in a letter to House and Senate appropriators that urges Congress to increase the FDA budget by $50 million to fully implement the Food Safety Modernization Act (FSMA).  Key components of FSMA include a focus on prevention and the creation of a comprehensive food import oversight system.
    9/16/2014

    IDSA Engages White House on FY 2016 Budget (PDF)

    IDSA wrote to the White House Office of Management and Budget (OMB) to highlight the need for additional resources in Fiscal Year (FY) 2016 to support the federal response to antimicrobial resistance as well as for rapid ID diagnostics R&D, immunization programs, pandemic preparedness, and global health.  The FY 2016 President's Budget Request is scheduled to be released on February 2, 2015.
    12/20/2013

    Groups Seek Support for Global TB Activities in Anticipation of FY2014 Funding Bill Release (PDF)

    IDSA joined other stakeholders in a letter to Congress seeking $236 million for USAID's TB programs in FY2014.  The letter discusses the impact of TB around the globe and makes special note of the emergence of multidrug-resistant and extensively drug-resistant TB.  USAID is a central partner in efforts to control TB in the world's 30 most highly burdened countries.
    6/22/2011

    Community Letter Advocating Robust Global Health Efforts (PDF)

    IDSA joined 53 other organizations to urge lawmakers to maintain its funding commitments to improving health in developing countries, without cutting other broader humanitarian efforts and development or imposing any new policy restrictions.
    11/5/2010

    TB Coalition Letter for Global and Domestic TB Funding (PDF)

    IDSA joined 16 other organizations to urge lawmakers to strengthen U.S. leadership in the fight against TB as envisioned in the Lantos-Hyde Act and Comprehensive TB Elimination Act by investing in global and domestic TB programs at USAID and CDC.

 

Average 0 out of 5

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site